vs
Side-by-side financial comparison of Journey Medical Corp (DERM) and EXAGEN INC. (XGN). Click either name above to swap in a different company.
EXAGEN INC. is the larger business by last-quarter revenue ($16.6M vs $16.1M, roughly 1.0× Journey Medical Corp). Journey Medical Corp runs the higher net margin — -7.8% vs -28.1%, a 20.3% gap on every dollar of revenue. On growth, Journey Medical Corp posted the faster year-over-year revenue change (27.3% vs 21.8%). Over the past eight quarters, Journey Medical Corp's revenue compounded faster (11.0% CAGR vs 7.4%).
Journey Medical Corp is a commercial-stage biopharmaceutical company specializing in dermatology treatments. It develops, manufactures and markets prescription and over-the-counter products addressing acne, atopic dermatitis, fungal skin infections and other dermal conditions, primarily serving healthcare providers and patients across the United States.
Exagen Inc. is a clinical diagnostics company specializing in developing, manufacturing, and commercializing proprietary testing solutions for autoimmune, rheumatic, and related chronic diseases. It mainly operates in the U.S. market, serving healthcare providers and patients to support accurate disease diagnosis and treatment monitoring.
DERM vs XGN — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $16.1M | $16.6M |
| Net Profit | $-1.2M | $-4.7M |
| Gross Margin | — | 55.4% |
| Operating Margin | -2.8% | -29.9% |
| Net Margin | -7.8% | -28.1% |
| Revenue YoY | 27.3% | 21.8% |
| Net Profit YoY | -182.0% | -24.2% |
| EPS (diluted) | $-0.04 | $-0.21 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $16.1M | $16.6M | ||
| Q3 25 | $17.0M | $17.2M | ||
| Q2 25 | $15.0M | $17.2M | ||
| Q1 25 | $13.1M | $15.5M | ||
| Q4 24 | $12.6M | $13.7M | ||
| Q3 24 | $14.6M | $12.5M | ||
| Q2 24 | $14.9M | $15.1M | ||
| Q1 24 | $13.0M | $14.4M |
| Q4 25 | $-1.2M | $-4.7M | ||
| Q3 25 | $-2.3M | $-7.1M | ||
| Q2 25 | $-3.8M | $-4.4M | ||
| Q1 25 | $-4.1M | $-3.8M | ||
| Q4 24 | $1.5M | $-3.8M | ||
| Q3 24 | $-2.4M | $-5.0M | ||
| Q2 24 | $-3.4M | $-3.0M | ||
| Q1 24 | $-10.4M | $-3.4M |
| Q4 25 | — | 55.4% | ||
| Q3 25 | — | 58.4% | ||
| Q2 25 | — | 60.4% | ||
| Q1 25 | — | 58.9% | ||
| Q4 24 | 82.3% | 62.1% | ||
| Q3 24 | 63.9% | 55.8% | ||
| Q2 24 | 56.0% | 60.1% | ||
| Q1 24 | 47.7% | 59.6% |
| Q4 25 | -2.8% | -29.9% | ||
| Q3 25 | -9.0% | -18.0% | ||
| Q2 25 | -19.2% | -15.3% | ||
| Q1 25 | -25.3% | -21.7% | ||
| Q4 24 | 17.7% | -24.8% | ||
| Q3 24 | -19.8% | -37.3% | ||
| Q2 24 | -19.7% | -17.2% | ||
| Q1 24 | -77.4% | -20.8% |
| Q4 25 | -7.8% | -28.1% | ||
| Q3 25 | -13.6% | -41.1% | ||
| Q2 25 | -25.3% | -25.8% | ||
| Q1 25 | -31.0% | -24.2% | ||
| Q4 24 | 12.1% | -27.5% | ||
| Q3 24 | -16.3% | -40.2% | ||
| Q2 24 | -22.6% | -19.7% | ||
| Q1 24 | -80.1% | -23.3% |
| Q4 25 | $-0.04 | $-0.21 | ||
| Q3 25 | $-0.09 | $-0.31 | ||
| Q2 25 | $-0.16 | $-0.21 | ||
| Q1 25 | $-0.18 | $-0.20 | ||
| Q4 24 | $0.10 | $-0.20 | ||
| Q3 24 | $-0.12 | $-0.28 | ||
| Q2 24 | $-0.17 | $-0.16 | ||
| Q1 24 | $-0.53 | $-0.19 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $24.1M | $32.2M |
| Total DebtLower is stronger | $25.3M | $22.9M |
| Stockholders' EquityBook value | $31.9M | $17.4M |
| Total Assets | $94.6M | $58.0M |
| Debt / EquityLower = less leverage | 0.79× | 1.31× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $24.1M | $32.2M | ||
| Q3 25 | $24.9M | $35.7M | ||
| Q2 25 | $20.3M | $30.0M | ||
| Q1 25 | $21.1M | $11.2M | ||
| Q4 24 | $20.3M | $22.0M | ||
| Q3 24 | $22.5M | $22.0M | ||
| Q2 24 | $23.9M | $24.5M | ||
| Q1 24 | $24.1M | $27.3M |
| Q4 25 | $25.3M | $22.9M | ||
| Q3 25 | $25.2M | $22.9M | ||
| Q2 25 | $25.1M | $23.0M | ||
| Q1 25 | $25.0M | $20.9M | ||
| Q4 24 | $24.9M | $20.2M | ||
| Q3 24 | $19.8M | $20.3M | ||
| Q2 24 | $19.7M | $20.3M | ||
| Q1 24 | $14.7M | $19.5M |
| Q4 25 | $31.9M | $17.4M | ||
| Q3 25 | $25.9M | $18.1M | ||
| Q2 25 | $19.2M | $21.0M | ||
| Q1 25 | $21.5M | $6.4M | ||
| Q4 24 | $20.1M | $9.5M | ||
| Q3 24 | $10.9M | $12.9M | ||
| Q2 24 | $11.3M | $17.6M | ||
| Q1 24 | $13.0M | $20.0M |
| Q4 25 | $94.6M | $58.0M | ||
| Q3 25 | $85.2M | $62.8M | ||
| Q2 25 | $81.2M | $58.8M | ||
| Q1 25 | $85.0M | $40.3M | ||
| Q4 24 | $80.2M | $44.7M | ||
| Q3 24 | $64.0M | $43.6M | ||
| Q2 24 | $65.2M | $49.3M | ||
| Q1 24 | $66.6M | $50.8M |
| Q4 25 | 0.79× | 1.31× | ||
| Q3 25 | 0.97× | 1.26× | ||
| Q2 25 | 1.30× | 1.09× | ||
| Q1 25 | 1.16× | 3.27× | ||
| Q4 24 | 1.24× | 2.12× | ||
| Q3 24 | 1.81× | 1.57× | ||
| Q2 24 | 1.75× | 1.15× | ||
| Q1 24 | 1.13× | 0.98× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-6.3M | $-3.0M |
| Free Cash FlowOCF − Capex | — | $-3.1M |
| FCF MarginFCF / Revenue | — | -18.4% |
| Capex IntensityCapex / Revenue | — | 0.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-14.3M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-6.3M | $-3.0M | ||
| Q3 25 | $-2.4M | $2.9M | ||
| Q2 25 | $-942.0K | $-2.9M | ||
| Q1 25 | $-2.8M | $-10.7M | ||
| Q4 24 | $2.2M | $363.0K | ||
| Q3 24 | $-1.2M | $-2.2M | ||
| Q2 24 | $-5.2M | $-2.4M | ||
| Q1 24 | $-5.0M | $-9.0M |
| Q4 25 | — | $-3.1M | ||
| Q3 25 | — | $2.7M | ||
| Q2 25 | — | $-3.1M | ||
| Q1 25 | — | $-10.8M | ||
| Q4 24 | — | $217.0K | ||
| Q3 24 | — | $-2.3M | ||
| Q2 24 | — | $-2.6M | ||
| Q1 24 | — | $-9.1M |
| Q4 25 | — | -18.4% | ||
| Q3 25 | — | 15.5% | ||
| Q2 25 | — | -18.0% | ||
| Q1 25 | — | -69.6% | ||
| Q4 24 | — | 1.6% | ||
| Q3 24 | — | -18.6% | ||
| Q2 24 | — | -17.0% | ||
| Q1 24 | — | -63.3% |
| Q4 25 | — | 0.3% | ||
| Q3 25 | — | 1.6% | ||
| Q2 25 | — | 1.2% | ||
| Q1 25 | — | 0.7% | ||
| Q4 24 | — | 1.1% | ||
| Q3 24 | — | 1.2% | ||
| Q2 24 | — | 0.9% | ||
| Q1 24 | — | 0.6% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.46× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DERM
| Qbrexza | $5.5M | 35% |
| Emrosi | $5.0M | 31% |
| Accutane | $3.1M | 19% |
| Other | $2.5M | 15% |
XGN
| Commercial | $9.3M | 56% |
| Government1 | $4.3M | 26% |
| Client Direct Bill | $2.9M | 18% |
